Stenotrophomonas maltophilia: Emerging problem an in cystic fibrosis patients

Reviews and Research in Medical Microbiology

Volumn 8, Issue 1, 1997, Pages 15-19

  Denton, M ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Cystic fibrosis; Stenotrophomonas maltophilia

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; COTRIMOXAZOLE; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIUM CULTURE; CYSTIC FIBROSIS; ENZYME SYNTHESIS; HUMAN; LUNG FUNCTION; OPPORTUNISTIC INFECTION; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; STENOTROPHOMONAS MALTOPHILIA;

EID: 0031028225     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199701000-00002     Document Type: Short Survey

References (35)

1. Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet 1993; 341: 1065-1069.
2. Moss RB. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin Infect Dis 1995; 21: 839-851.
3. Hoiby N. Pseudomonas infection in cystic fibrosis. In: Dodge JA, Brock DJH, Widdicombe JH, eds. Cystic fibrosis - current topics: volume 1, Chichester: Wiley, 1993.
4. Hugh R, Ryschenkow E. Pseudomonas maltophila, an Alcaligenes-like species. J Gen Microbiol 1961; 26: 123-132.
5. Swings J, De Vos P, Van den Mooter M, De -Ley J. Transfer of Pseudomonas maltophilia Hugh 1981 to the genus Xanthomonas as Xanthomonas maltophilia (Hugh 1981) comb. nov. Int J Syst Bacteriol 1983; 33: 409-413.
6. Palleroni NJ, Bradbury JF. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int J Syst Bacteriol 1993; 43: 606-609.
7. Khardori N, Elting L, Wong E, Schable B, Bodey GP. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990; 12: 997-1003.
8. Villarino ME, Stevens LE, Schable B, et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonisation in intensive care unit patients. Infect Cont Hosp Epidemiol 1992; 13: 201-206.
9. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30 (Supplement): 453-464.
10. Gerner-Smidt P, Bruun B, Arpi M, Schmidt J. Diversity of nosocomial Xanthomonas maltophilia (Stenotrophomonas maltophilia) as determined by ribotyping. Eur J Clin Microbiol Infect Dis 1995; 14: 137-140.
11. Davin-Regli A, Bollet C, Auffray JP, Saux P, De Micco P. Use of random amplified polymorphic DNA for epidemiological typing of Stenotrophomonas maltophilia. J Hosp Infect 1996; 32: 39-50.
12. Gladman G, Connor PJ, Williams RF, David TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child 1992; 67: 192-195.
13. Denton M, Hall MJ, Todd NJ, Littlewood JM. A novel selective culture medium reveals a previously underestimated prevalence of Stenotrophomonas (Xanthomonas) maltophilia in a cystic fibrosis clinic. Abstracts of the 20th European Cystic Fibrosis Conference, Brussels, Belgium, 1995, Abstr. P14.
14. Burdge DR, Noble MA, Campbell ME, Krell VL, Speert DP. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis 1995; 20: 445-448.
15. Isles A, Maclusky I, Corey M et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984; 104: 206-210.
16. Frederiksen B, Hoiby N, Koch C. Stenotrophomonas (Xanthomonas) maltophilia at the Danish Cystic Fibrosis Centre, 1974-1993. Pediatr Pulmon 1995; suppl 12: abstr 383, p 287.
17. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72: 651-657.
18. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation at cystic fibrosis by early treatment. Lancet 1991; 338: 725-726.
19. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas aeruginosa colonisation in cystic fibrosis. Lancet 1985; i: 865.
20. Vazquez C, Munico M, Corera M, Gaztelurrutia L, Sojo A, Vitoria JC. Early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Acta Paediatr 1993; 82: 308-309.
21. Denton M, Todd NJ, Littlewood JM. Role of antipseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996; 15: 402-405.
22. Frederiksen B, Hoiby N, Bingen E, Brahimi N. Epidemiology of Xanthomonas maltophilia at the Danish Cystic Fibrosis Center. Abstracts of the European Cystic Fibrosis Conference 1994, abstr no. P39.
23. Denton M, Todd NJ, Littlewood JM, Hawkey PM. Molecular epidemiology of Stenotrophomonas maltophilia isolated from cystic fibrosis patients. J Infect 1996; 32: 88.
24. Hutchinson GR, Parker S, Pryor JA, et al. Home-use nebulisers: a potential primary source of Burkholderia capacia and other colistin-resistant gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996; 34: 584-587.
25. Bottone EJ, Reitano M, Janda JM Troy K, Cuttner J. Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum. J Clin Microbiol 1986; 24: 995-997.
26. Irifune K, Ishida T, Shimoguchi K, et al. Pneumonia caused by Stenotrophomonas maltophilia with a mucoid phenotype. J Clin Microbiol 1994; 32: 2856-2857.
27. Demko C, Doershuk C, Stern R. Thirteen year experience with Xanthomonas maltophilia in patients with cystic fibrosis. Pediatr Pulmon 1995; suppl 12: abstr 233, p 244.
28. Karpati F, Malmborg AS, Alfredsson H, Hjelte L. Bacterial colonisation with Xanthomonas maltophilia - a retrospective study in a cystic fibrosis patient population. Infection 1994; 22: 258-263.
29. Ballestero S, Virseda I, Escobar H, Suarez L, Baquero F. Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1995; 14: 728-729.
30. Govan JRW, Nelson JW. Microbiology of lung infection in cystic fibrosis. Brit Med Bull 1992; 48: 912-930.
31. Chatelut M, Dournes JL, Chabanon G, Marty N. Epidemiological typing of Stenotrophomonas (Xanthomonas) maltophilia by PCR. J Clin Microbiol 1995; 33: 912-914.
32. Paton R, Miles RS, Amyes SGB. Biochemical properties of inducible β-lactamases produced from Xanthomonas maltophilia. Antimicrob Ag Chemother 1994; 38: 2143-2149.
33. Mett H, Rosta S, Schacher B, Frei R. Outer membrane permeability and β-lactamase content in Pseudomonas maltophilia clinical isolates and laboratory mutants. Rev Infect Dis 1988; 10: 765-769.
34. Bauernfeind A, Bertele RM, Harms K, et al. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 1987; 15: 270-277.
35. Hoppe JE, Theurer-Mainka U, Stern M. Comparison of three methods for culturing throat swabs from cystic fibrosis patients. J Clin Microbiol 1995; 33: 1896-1898.